Comparing CervoMed (CRVO) & Its Competitors

CervoMed (NASDAQ:CRVO) is one of 1,077 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare CervoMed to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

Insider and Institutional Ownership

25.1% of CervoMed shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 35.4% of CervoMed shares are owned by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

CervoMed has a beta of -0.73, meaning that its stock price is 173% less volatile than the S&P 500. Comparatively, CervoMed’s rivals have a beta of 4.18, meaning that their average stock price is 318% more volatile than the S&P 500.

Profitability

This table compares CervoMed and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CervoMed	-118.68%	-44.11%	-39.81%
CervoMed Competitors	-3,399.87%	-235.11%	-32.77%

Earnings and Valuation

This table compares CervoMed and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CervoMed	$7.14 million	-$2.17 million	-3.55
CervoMed Competitors	$9.91 billion	$136.15 million	-5.39

CervoMed’s rivals have higher revenue and earnings than CervoMed. CervoMed is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for CervoMed and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1	1	5	2	2.89
CervoMed Competitors	8823	22864	51297	1435	2.54

CervoMed currently has a consensus price target of $27.63, suggesting a potential upside of 256.91%. As a group, “Pharmaceutical preparations” companies have a potential upside of 2,439.56%. Given CervoMed’s rivals higher probable upside, analysts clearly believe CervoMed has less favorable growth aspects than its rivals.

Summary

CervoMed rivals beat CervoMed on 7 of the 13 factors compared.

CervoMed Company Profile

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.